- Home
- IMSR vs AARD Comparison
IMSR vs AARD Comparison
Compare IMSR & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMSR | AARD |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.8M | 231.9M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | IMSR | AARD |
|---|---|---|
| Price | $8.32 | $14.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $30.63 |
| AVG Volume (30 Days) | ★ 1.8M | 219.1K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1234.25 | N/A |
| 52 Week Low | $7.52 | $4.88 |
| 52 Week High | $31.50 | $19.58 |
Technical Indicators
Market Signals| Indicator | IMSR | AARD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 65.38 |
| Support Level | N/A | $14.27 |
| Resistance Level | N/A | $16.00 |
| Average True Range (ATR) | 0.00 | 1.07 |
| MACD | 0.00 | 0.52 |
| Stochastic Oscillator | 0.00 | 79.91 |
Price Performance
Historical ComparisonAbout IMSR Terrestrial Energy Inc.
Terrestrial Energy Inc is an industry-leading technology company committed to delivering reliable, emission-free, and cost-competitive nuclear energy with a transformative advanced reactor, the Integral Molten Salt Reactor (IMSR). Its mission is to transform global energy markets by commercializing its IMSR Plant, which will deliver low-carbon electricity and industrial heat with superior economics, speed to deployment, and siting flexibility.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.